menu toggle
Memorial Day
Cencora will be closed in observance of the Memorial Day holiday and there will be no deliveries on Monday, May 27. Our Customer Service and Customer Systems Support teams will also be unavailable on this day. Please review our full holiday schedule below for more detailed information and to plan your orders accordingly. We will resume normal operations on Tuesday, May 28
Review full holiday schedule

Coronavirus (COVID-19) Updates

AmerisourceBergen and our global pharmaceutical healthcare businesses are monitoring the ongoing spread of the novel COVID-19 coronavirus.

As an active participant in the global pharmaceutical supply chain, we’re engaged with government and healthcare officials as these agencies and experts closely monitor the spread of COVID-19. We have business continuity plans that include our global workforce and our teams are in daily communications with manufacturers, monitoring inventory levels and customer purchasing behavior for any potential impact to the product supply chain.

We will continue to be highly engaged as the situation evolves on a day-to-day basis and will post updates here for our customers. 

Update on the Distribution of Remdesivir from Gilead Sciences

On May 1, 2020, the FDA granted an Emergency Use Authorization (EUA) for Gilead’s remdesivir for the treatment of COVID-19.  In the weeks that followed, Gilead worked closely with the U.S. Government to donate and distribute remdesivir across the country to treat critical COVID-19 patients and worked with AmerisourceBergen as the sole distributor for the donated remdesivir. 

On June 29, 2020, after the initial donation period ended, the Department of Health and Human Services (HHS) announced an agreement to secure large supplies of remdesivir for the United States from Gilead Sciences through September, allowing U.S. hospitals to purchase the drug in amounts allocated by HHS and state health departments. HHS secured more than 500,000 treatment courses of the drug through September. It was also announced that AmerisourceBergen would remain the sole distributor for the commercially available remdesivir.

Hospitals that are allocated remdesivir by their State Department of Health are not charged more than Gilead’s Wholesale Acquisition Cost (WAC), which is approximately $3,200 per treatment course. 

HHS allocates product to state and territorial health departments, and health departments allocate it to hospitals. The delivery of the purchased remdesivir delivered directly from AmerisourceBergen to the hospital identified by the State Department of Health.

For further information on the donated remdesivir, please see HHS’ Public Health Emergency webpage on remdesivir, available at https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Pages/remdesivir.aspx. 

For further information on the EUA remdesivir, please see HHS’ June 29, 2020 announcement available at https://www.hhs.gov/about/news/2020/06/29/trump-administration-secures-new-supplies-remdesivir-united-states.html.
 
Retail and specialty pharmacies are not eligible to receive donated remdesivir.

  • For questions about the distribution of remdesivir, call the national remdesivir donation inquiry line at 877-987-4987. To ask if your hospital has been allocated remdesivir by your State Department of Health, email remdesivir@amerisourcebergen.com. 
  • For information on clinical trials that are testing the use of remdesivir in COVID-19, please visit www.clinicaltrials.gov.
  • For additional medical information about remdesivir, please visit https://www.askgileadmedical.com/remdesivir/ or call 1-866-MEDI-GSI (1-866-633-4474) Monday – Friday, 6am – 4pm PT.

We will update this message as additional information becomes available.